Skip to main content
Top
Published in: BMC Infectious Diseases 1/2013

Open Access 01-12-2013 | Research article

Non-AIDS defining cancers in the D:A:D Study - time trends and predictors of survival: a cohort study

Authors: Signe W Worm, Mark Bower, Peter Reiss, Fabrice Bonnet, Matthew Law, Gerd Fätkenheuer, Antonella d’Arminio Monforte, Donald I Abrams, Andrew Grulich, Eric Fontas, Ole Kirk, Hansjakob Furrer, Stephane De Wit, Andrew Phillips, Jens D Lundgren, Caroline A Sabin, for the D:A:D Study Group

Published in: BMC Infectious Diseases | Issue 1/2013

Login to get access

Abstract

Background

Non-AIDS defining cancers (NADC) are an important cause of morbidity and mortality in HIV-positive individuals. Using data from a large international cohort of HIV-positive individuals, we described the incidence of NADC from 2004–2010, and described subsequent mortality and predictors of these.

Methods

Individuals were followed from 1st January 2004/enrolment in study, until the earliest of a new NADC, 1st February 2010, death or six months after the patient’s last visit. Incidence rates were estimated for each year of follow-up, overall and stratified by gender, age and mode of HIV acquisition. Cumulative risk of mortality following NADC diagnosis was summarised using Kaplan-Meier methods, with follow-up for these analyses from the date of NADC diagnosis until the patient’s death, 1st February 2010 or 6 months after the patient’s last visit. Factors associated with mortality following NADC diagnosis were identified using multivariable Cox proportional hazards regression.

Results

Over 176,775 person-years (PY), 880 (2.1%) patients developed a new NADC (incidence: 4.98/1000PY [95% confidence interval 4.65, 5.31]). Over a third of these patients (327, 37.2%) had died by 1st February 2010. Time trends for lung cancer, anal cancer and Hodgkin’s lymphoma were broadly consistent. Kaplan-Meier cumulative mortality estimates at 1, 3 and 5 years after NADC diagnosis were 28.2% [95% CI 25.1-31.2], 42.0% [38.2-45.8] and 47.3% [42.4-52.2], respectively. Significant predictors of poorer survival after diagnosis of NADC were lung cancer (compared to other cancer types), male gender, non-white ethnicity, and smoking status. Later year of diagnosis and higher CD4 count at NADC diagnosis were associated with improved survival. The incidence of NADC remained stable over the period 2004–2010 in this large observational cohort.

Conclusions

The prognosis after diagnosis of NADC, in particular lung cancer and disseminated cancer, is poor but has improved somewhat over time. Modifiable risk factors, such as smoking and low CD4 counts, were associated with mortality following a diagnosis of NADC.
Appendix
Available only for authorised users
Literature
1.
go back to reference Mocroft A, Ledergerber B, Katlama C, et al: Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet. 2003, 362: 22-29. 10.1016/S0140-6736(03)13802-0.CrossRefPubMed Mocroft A, Ledergerber B, Katlama C, et al: Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet. 2003, 362: 22-29. 10.1016/S0140-6736(03)13802-0.CrossRefPubMed
2.
go back to reference Engels EA, Pfeiffer RM, Goedert JJ, et al: Trends in cancer risk among people with AIDS in the United States 1980–2002. AIDS. 2006, 20: 1645-1654. 10.1097/01.aids.0000238411.75324.59.CrossRefPubMed Engels EA, Pfeiffer RM, Goedert JJ, et al: Trends in cancer risk among people with AIDS in the United States 1980–2002. AIDS. 2006, 20: 1645-1654. 10.1097/01.aids.0000238411.75324.59.CrossRefPubMed
3.
go back to reference Simard EP, Pfeiffer RM, Engels EA: Spectrum of cancer risk late after AIDS onset in the United States. Arch Intern Med. 2010, 170: 1337-1345. 10.1001/archinternmed.2010.253.CrossRefPubMedPubMedCentral Simard EP, Pfeiffer RM, Engels EA: Spectrum of cancer risk late after AIDS onset in the United States. Arch Intern Med. 2010, 170: 1337-1345. 10.1001/archinternmed.2010.253.CrossRefPubMedPubMedCentral
4.
go back to reference Shiels MS, Pfeiffer RM, Gail MH, et al: Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst. 2011, 103: 753-762. 10.1093/jnci/djr076.CrossRefPubMedPubMedCentral Shiels MS, Pfeiffer RM, Gail MH, et al: Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst. 2011, 103: 753-762. 10.1093/jnci/djr076.CrossRefPubMedPubMedCentral
5.
go back to reference Patel P, Hanson DL, Sullivan PS, et al: Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992–2003. Ann Intern Med. 2008, 148: 728-736. 10.7326/0003-4819-148-10-200805200-00005.CrossRefPubMed Patel P, Hanson DL, Sullivan PS, et al: Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992–2003. Ann Intern Med. 2008, 148: 728-736. 10.7326/0003-4819-148-10-200805200-00005.CrossRefPubMed
6.
go back to reference Powles T, Robinson D, Stebbing J, et al: Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. J Clin Oncol. 2009, 27: 884-890. 10.1200/JCO.2008.19.6626.CrossRefPubMed Powles T, Robinson D, Stebbing J, et al: Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. J Clin Oncol. 2009, 27: 884-890. 10.1200/JCO.2008.19.6626.CrossRefPubMed
7.
go back to reference Franceschi S, Lise M, Clifford GM, et al: Changing patterns of cancer incidence in the early-and late-HAART periods: the Swiss HIV cohort study. Brit J Cancer. 2010, 103: 416-422. 10.1038/sj.bjc.6605756.CrossRefPubMedPubMedCentral Franceschi S, Lise M, Clifford GM, et al: Changing patterns of cancer incidence in the early-and late-HAART periods: the Swiss HIV cohort study. Brit J Cancer. 2010, 103: 416-422. 10.1038/sj.bjc.6605756.CrossRefPubMedPubMedCentral
8.
go back to reference Long JL, Engels EA, Moore RD, Gebo KA: Incidence and outcomes of malignancy in the HAART era in an urban cohort of HIV-infected individuals. AIDS. 2008, 22: 489-496. 10.1097/QAD.0b013e3282f47082.CrossRefPubMedPubMedCentral Long JL, Engels EA, Moore RD, Gebo KA: Incidence and outcomes of malignancy in the HAART era in an urban cohort of HIV-infected individuals. AIDS. 2008, 22: 489-496. 10.1097/QAD.0b013e3282f47082.CrossRefPubMedPubMedCentral
9.
go back to reference Hessol NA, Pipkin S, Schwarcz S, Cress RD, Bacchetti P, Scheer S: The impact of highly active antiretroviral therapy on non-AIDS-defining cancers among adults with AIDS. Am J Epidemiol. 2007, 165: 1143-1153. 10.1093/aje/kwm017.CrossRefPubMed Hessol NA, Pipkin S, Schwarcz S, Cress RD, Bacchetti P, Scheer S: The impact of highly active antiretroviral therapy on non-AIDS-defining cancers among adults with AIDS. Am J Epidemiol. 2007, 165: 1143-1153. 10.1093/aje/kwm017.CrossRefPubMed
10.
go back to reference Silverberg MJ, Lau B, Justice AC, et al: Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Clin Infect Dis. 2012, 54: 1026-1034. 10.1093/cid/cir1012.CrossRefPubMedPubMedCentral Silverberg MJ, Lau B, Justice AC, et al: Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Clin Infect Dis. 2012, 54: 1026-1034. 10.1093/cid/cir1012.CrossRefPubMedPubMedCentral
11.
go back to reference Piketty C, Selinger-Leneman H, Bouvier AM, et al: Incidence of HIV-related anal cancer remains increased despite long-term combined antiretroviral treatment: results from the French Hospital Database on HIV. J Clin Oncol. 2012, 30: 4360-4366. 10.1200/JCO.2012.44.5486.CrossRefPubMed Piketty C, Selinger-Leneman H, Bouvier AM, et al: Incidence of HIV-related anal cancer remains increased despite long-term combined antiretroviral treatment: results from the French Hospital Database on HIV. J Clin Oncol. 2012, 30: 4360-4366. 10.1200/JCO.2012.44.5486.CrossRefPubMed
12.
go back to reference Bonnet F, Burty C, Lewden C, et al: Changes in cancer mortality among HIV-infected patients: the Mortalite 2005 Survey. Clin Infect Dis. 2009, 48: 633-639. 10.1086/596766.CrossRefPubMed Bonnet F, Burty C, Lewden C, et al: Changes in cancer mortality among HIV-infected patients: the Mortalite 2005 Survey. Clin Infect Dis. 2009, 48: 633-639. 10.1086/596766.CrossRefPubMed
13.
14.
go back to reference Hasse B, Ledergerber B, Furrer H, et al: Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study. Clin Infect Dis. 2011, 53: 1130-1139. 10.1093/cid/cir626.CrossRefPubMed Hasse B, Ledergerber B, Furrer H, et al: Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study. Clin Infect Dis. 2011, 53: 1130-1139. 10.1093/cid/cir626.CrossRefPubMed
15.
go back to reference Lowsky R, Lipton J, Fyles G, et al: Secondary malignancies after bone marrow transplantation in adults. J Clin Oncol. 1994, 12: 2187-2192.PubMed Lowsky R, Lipton J, Fyles G, et al: Secondary malignancies after bone marrow transplantation in adults. J Clin Oncol. 1994, 12: 2187-2192.PubMed
16.
go back to reference Curtis RE, Rowlings PA, Deeg HJ, et al: Solid cancers after bone marrow transplantation. N Engl J Med. 1997, 336: 897-904. 10.1056/NEJM199703273361301.CrossRefPubMed Curtis RE, Rowlings PA, Deeg HJ, et al: Solid cancers after bone marrow transplantation. N Engl J Med. 1997, 336: 897-904. 10.1056/NEJM199703273361301.CrossRefPubMed
17.
go back to reference Tirelli U, Errante D, Dolcetti R, et al: Hodgkin’s disease and human immunodeficiency virus infection: clinicopathologic and virologic features of 114 patients from the Italian cooperative group on AIDS and tumors. J Clin Oncol. 1995, 13: 1758-1767.PubMed Tirelli U, Errante D, Dolcetti R, et al: Hodgkin’s disease and human immunodeficiency virus infection: clinicopathologic and virologic features of 114 patients from the Italian cooperative group on AIDS and tumors. J Clin Oncol. 1995, 13: 1758-1767.PubMed
18.
go back to reference Biggar RJ, Engels EA, Ly S, et al: Survival after cancer diagnosis in persons with AIDS. J Acquir Imm Defic Syndr. 2005, 39: 293-299. 10.1097/01.qai.0000164033.02947.e3.CrossRef Biggar RJ, Engels EA, Ly S, et al: Survival after cancer diagnosis in persons with AIDS. J Acquir Imm Defic Syndr. 2005, 39: 293-299. 10.1097/01.qai.0000164033.02947.e3.CrossRef
19.
go back to reference Achenbach CJ, Cole SR, Kitahata MM, et al: Mortality after cancer diagnosis in HIV-infected individuals treated with antiretroviral therapy. AIDS. 2011, 25: 691-700. 10.1097/QAD.0b013e3283437f77.CrossRefPubMedPubMedCentral Achenbach CJ, Cole SR, Kitahata MM, et al: Mortality after cancer diagnosis in HIV-infected individuals treated with antiretroviral therapy. AIDS. 2011, 25: 691-700. 10.1097/QAD.0b013e3283437f77.CrossRefPubMedPubMedCentral
20.
go back to reference Clifford GM, Polesel J, Rickenbach M, et al: Cancer risk in the Swiss HIV cohort study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst. 2005, 97: 425-432. 10.1093/jnci/dji072.CrossRefPubMed Clifford GM, Polesel J, Rickenbach M, et al: Cancer risk in the Swiss HIV cohort study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst. 2005, 97: 425-432. 10.1093/jnci/dji072.CrossRefPubMed
21.
go back to reference Friis-Møller N, Sabin CA, Weber R, et al: Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003, 349: 1993-2003.CrossRefPubMed Friis-Møller N, Sabin CA, Weber R, et al: Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003, 349: 1993-2003.CrossRefPubMed
22.
go back to reference Kowalska JD, Friis-Moller N, Kirk O, et al: The coding causes of death in HIV (CoDe) Project: initial results and evaluation of methodology. Epidemiology. 2011, 22: 516-523. 10.1097/EDE.0b013e31821b5332.CrossRefPubMed Kowalska JD, Friis-Moller N, Kirk O, et al: The coding causes of death in HIV (CoDe) Project: initial results and evaluation of methodology. Epidemiology. 2011, 22: 516-523. 10.1097/EDE.0b013e31821b5332.CrossRefPubMed
23.
go back to reference Reekie J, Kosa C, Engsig F, et al: Relationship between current level of immunodeficiency and non-acquired immunodeficiency syndrome-defining malignancies. Cancer. 2010, 116: 5306-5315. 10.1002/cncr.25311.CrossRefPubMed Reekie J, Kosa C, Engsig F, et al: Relationship between current level of immunodeficiency and non-acquired immunodeficiency syndrome-defining malignancies. Cancer. 2010, 116: 5306-5315. 10.1002/cncr.25311.CrossRefPubMed
24.
go back to reference Herida M, Mary-Krause M, Kaphan R, et al: Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. J Clin Oncol. 2003, 21: 3447-3453. 10.1200/JCO.2003.01.096.CrossRefPubMed Herida M, Mary-Krause M, Kaphan R, et al: Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. J Clin Oncol. 2003, 21: 3447-3453. 10.1200/JCO.2003.01.096.CrossRefPubMed
25.
go back to reference Spagnuolo V, Galli L, Salpietro S, et al: Ten-year survival among HIV-1-infected subjects with AIDS or non-AIDS-defining malignancies. Int J Cancer. 2012, 130: 2990-2996. 10.1002/ijc.26332.CrossRefPubMed Spagnuolo V, Galli L, Salpietro S, et al: Ten-year survival among HIV-1-infected subjects with AIDS or non-AIDS-defining malignancies. Int J Cancer. 2012, 130: 2990-2996. 10.1002/ijc.26332.CrossRefPubMed
26.
go back to reference Machalek DA, Poynten M, Jin F, et al: Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis. Lancet Oncol. 2012, 13: 487-500. 10.1016/S1470-2045(12)70080-3.CrossRefPubMed Machalek DA, Poynten M, Jin F, et al: Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis. Lancet Oncol. 2012, 13: 487-500. 10.1016/S1470-2045(12)70080-3.CrossRefPubMed
27.
go back to reference Jin F, Stein AN, Conway EL, et al: Trends in anal cancer in Australia 1982–2005. Vaccine. 2011, 29: 2322-2327. 10.1016/j.vaccine.2011.01.015.CrossRefPubMed Jin F, Stein AN, Conway EL, et al: Trends in anal cancer in Australia 1982–2005. Vaccine. 2011, 29: 2322-2327. 10.1016/j.vaccine.2011.01.015.CrossRefPubMed
28.
go back to reference Grulich AE, Li Y, McDonald A, Correll PK, Law MG, Kaldor JM: Rates of non-AIDS-defining cancers in people with HIV infection before and after AIDS diagnosis. AIDS. 2002, 16: 1155-1161. 10.1097/00002030-200205240-00009.CrossRefPubMed Grulich AE, Li Y, McDonald A, Correll PK, Law MG, Kaldor JM: Rates of non-AIDS-defining cancers in people with HIV infection before and after AIDS diagnosis. AIDS. 2002, 16: 1155-1161. 10.1097/00002030-200205240-00009.CrossRefPubMed
29.
go back to reference Shiels MS, Cole SR, Mehta SH, Kirk GD: Lung cancer incidence and mortality among HIV-infected and HIV-uninfected injection drug users. J Aquir Immune Defic Syndr. 2010, 55: 510-515. 10.1097/QAI.0b013e3181f53783.CrossRef Shiels MS, Cole SR, Mehta SH, Kirk GD: Lung cancer incidence and mortality among HIV-infected and HIV-uninfected injection drug users. J Aquir Immune Defic Syndr. 2010, 55: 510-515. 10.1097/QAI.0b013e3181f53783.CrossRef
30.
go back to reference Hoffmann C, Chow KU, Wolf E, et al: Strong impact of highly active antiretroviral therapy on survival in patients with human immunodeficiency virus-associated Hodgkin’s disease. Br J Haematol. 2004, 125: 455-462. 10.1111/j.1365-2141.2004.04934.x.CrossRefPubMed Hoffmann C, Chow KU, Wolf E, et al: Strong impact of highly active antiretroviral therapy on survival in patients with human immunodeficiency virus-associated Hodgkin’s disease. Br J Haematol. 2004, 125: 455-462. 10.1111/j.1365-2141.2004.04934.x.CrossRefPubMed
31.
go back to reference Xicoy B, Ribera JM, Miralles P, et al: Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin’s lymphoma. Haematologica. 2007, 92: 191-198. 10.3324/haematol.10479.CrossRefPubMed Xicoy B, Ribera JM, Miralles P, et al: Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin’s lymphoma. Haematologica. 2007, 92: 191-198. 10.3324/haematol.10479.CrossRefPubMed
32.
go back to reference Bower M, Powles T, Newsom-Davis T, et al: HIV-associated anal cancer: has highly active antiretroviral therapy reduced the incidence or improved the outcome?. J Acquir Immune Defic Syndr. 2004, 37: 1563-1565. 10.1097/00126334-200412150-00004.CrossRefPubMed Bower M, Powles T, Newsom-Davis T, et al: HIV-associated anal cancer: has highly active antiretroviral therapy reduced the incidence or improved the outcome?. J Acquir Immune Defic Syndr. 2004, 37: 1563-1565. 10.1097/00126334-200412150-00004.CrossRefPubMed
33.
go back to reference Munoz-Bongrand N, Poghosyan T, Zohar S, et al: Anal carcinoma in HIV-infected patients in the era of antiretroviral therapy: a comparative study. Dis Colon Rectum. 2011, 54: 729-735. 10.1007/DCR.0b013e3182137de9.CrossRefPubMed Munoz-Bongrand N, Poghosyan T, Zohar S, et al: Anal carcinoma in HIV-infected patients in the era of antiretroviral therapy: a comparative study. Dis Colon Rectum. 2011, 54: 729-735. 10.1007/DCR.0b013e3182137de9.CrossRefPubMed
Metadata
Title
Non-AIDS defining cancers in the D:A:D Study - time trends and predictors of survival: a cohort study
Authors
Signe W Worm
Mark Bower
Peter Reiss
Fabrice Bonnet
Matthew Law
Gerd Fätkenheuer
Antonella d’Arminio Monforte
Donald I Abrams
Andrew Grulich
Eric Fontas
Ole Kirk
Hansjakob Furrer
Stephane De Wit
Andrew Phillips
Jens D Lundgren
Caroline A Sabin
for the D:A:D Study Group
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2013
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/1471-2334-13-471

Other articles of this Issue 1/2013

BMC Infectious Diseases 1/2013 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.